TUDCA has not been directly studied in pregnant humans, so there is no established safety rating for its use during pregnancy. While TUDCA is a naturally occurring bile acid in the human body and animal studies have shown promising results, the lack of human pregnancy data means it falls into a gray area. Its closely related parent compound, ursodeoxycholic acid (UDCA), is FDA-approved and widely prescribed during pregnancy for liver conditions, which provides some indirect reassurance but not a green light for TUDCA supplements.
What TUDCA Is and How It Relates to UDCA
TUDCA (tauroursodeoxycholic acid) is a taurine-conjugated form of UDCA. Your body actually produces small amounts of TUDCA naturally when bile acids interact with gut bacteria. As a supplement, it’s marketed for liver support, digestive health, and cellular protection. The key distinction for pregnant people is that UDCA is a prescription medication with decades of clinical use in pregnancy, while TUDCA is sold as an unregulated dietary supplement without the same body of human safety data.
UDCA is the first-line treatment for intrahepatic cholestasis of pregnancy (ICP), a liver condition that causes intense itching and elevated bile acids during the second and third trimesters. Major medical organizations, including the Society for Maternal-Fetal Medicine and the European Association for the Study of the Liver, endorse UDCA for this purpose. Because TUDCA is chemically derived from UDCA, some people assume equivalent safety, but that assumption hasn’t been verified in human pregnancy trials.
What Animal Studies Show
The most relevant research comes from rat models studying pregnancy in older maternal age. In these studies, TUDCA treatment during pregnancy improved fetal body weight in both male and female offspring from aged mothers. Specifically, fetal weight was reduced in pups from older rats compared to younger ones, and TUDCA reversed that reduction in both sexes. TUDCA also improved the ratio of fetal weight to placental weight in female offspring, suggesting better placental efficiency. No harmful fetal effects were reported in these studies.
The mechanism appears to involve reducing a type of cellular stress in the placenta. In older pregnant rats, certain stress markers in the placenta were elevated, and TUDCA brought those markers back down to normal levels. Researchers also observed a tendency toward improved blood flow in the uterine artery with TUDCA treatment. These are encouraging findings, but rat physiology differs enough from human physiology that these results can’t be directly applied to pregnant people.
Side Effects in Non-Pregnant Adults
In clinical studies on non-pregnant adults, TUDCA has a very mild side effect profile. In one trial where patients with chronic active hepatitis took 500 mg per day (split into two doses with meals) for three months, none of the patients reported side effects. TUDCA significantly lowered key liver enzymes: AST dropped by 44%, ALT by 49%, and GGT by 38%. Bilirubin and alkaline phosphatase stayed within normal ranges throughout. The treatment also improved digestive symptoms like bloating, nausea, and upper abdominal discomfort.
That said, a clean safety profile in non-pregnant adults with liver disease doesn’t guarantee the same in pregnancy. Pregnancy changes how the body metabolizes substances, alters bile acid circulation, and introduces a developing fetus into the equation.
The Supplement vs. Prescription Problem
One of the biggest practical concerns with TUDCA during pregnancy isn’t the compound itself but the fact that it’s an unregulated supplement. Unlike prescription UDCA, TUDCA supplements aren’t subject to the same manufacturing standards, purity testing, or dosage consistency required of pharmaceuticals. A bottle of TUDCA from a supplement company may contain fillers, contaminants, or doses that don’t match the label. During pregnancy, when even small exposures matter, this lack of quality control adds a layer of risk that exists independent of TUDCA’s biological effects.
UDCA Safety During Breastfeeding
For those wondering about the postpartum period, research on UDCA (TUDCA’s parent compound) during breastfeeding is reassuring. A study of 20 breastfeeding patients taking UDCA at doses between 500 and 1,500 mg daily found that total bile acid concentrations in breast milk were identical between treated patients and untreated controls (3.2 µmol/L in both groups). UDCA appeared in breast milk only in negligible amounts, around 0.69 µmol/L, and did not meaningfully contribute to the newborn’s bile acid levels. No side effects were observed in any of the infants, and routine follow-ups at one year showed normal development. No equivalent study exists for TUDCA specifically during breastfeeding.
Approved Alternatives for Liver Support in Pregnancy
If you’re dealing with a diagnosed liver condition during pregnancy, several options have stronger evidence behind them. UDCA remains the standard treatment for intrahepatic cholestasis of pregnancy. For patients who can’t tolerate UDCA, the Society for Maternal-Fetal Medicine recommends SAMe (S-adenosylmethionine) or cholestyramine as alternatives. SAMe in particular is endorsed by multiple international guidelines for managing ICP.
Other hepatoprotective agents studied in pregnant patients include polyenylphosphatidylcholine (PPC) and glutathione. Three clinical trials on PPC in ICP patients found it lowered liver enzymes without causing adverse fetal events. Limited evidence on glutathione also suggests it is effective and safe in this context. None of these alternatives have been associated with severe adverse events in pregnant patients. All of them, however, should be used under medical supervision rather than self-prescribed.
The Bottom Line on TUDCA and Pregnancy
TUDCA is a naturally occurring bile acid with a favorable safety profile in non-pregnant adults and positive outcomes in pregnant animal models. Its parent compound UDCA has a well-established track record of safe use during pregnancy. But TUDCA itself has never been tested in a human pregnancy trial, and the supplement form introduces quality control concerns that prescription medications don’t carry. If you’re considering TUDCA for liver support or any other reason during pregnancy, the safer path is discussing prescription UDCA or other clinically validated options with your provider rather than self-supplementing with an unregulated product.